NCT07770802尚未招募1 期
A Phase Ib, Open-Label Clinical Study of HS-IT101 Injection in Patients With Advanced Renal Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 15
- 主要终点
- safety and tolerability
研究概览
简要总结
A Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and Subsequent Interleukin-2 Therapy in Patients with Advanced Renal Cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 years；
- •Histologically or cytologically confirmed advanced clear cell renal cell carcinoma；
- •At least one measurable lesion per RECIST 1.1；
- •ECOG performance status of 0 or 1；
- •Life expectancy of at least 3 months；
- •Adequate hematologic, hepatic, and renal function；
- •Washout period of at least 4 weeks since prior anticancer therapy；
- •Recovery from prior treatment-related adverse events to ≤ Grade 1 or baseline；
- •Signed informed consent obtained before any study procedures。
排除标准
- •Use of any immunosuppressive medications, such as corticosteroids, within 4 weeks prior to tumor tissue collection, or presence of a concurrent disease requiring immunosuppressive medication during the study as judged by the investigator. Intranasal or topical corticosteroid use is allowed.
- •Major organ surgery or significant trauma within 4 weeks prior to screening, or requirement for elective surgery during the study, except cytoreductive surgery performed for tumor tissue collection.
- •Received systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to tumor tissue collection.
- •Received a live vaccine within 3 months prior to screening, or plans to receive a live vaccine during the study.
- •History of severe hypersensitivity reaction to any drug used in the study.
- •Prior treatment with similar cell therapy products.
- •Prior organ transplantation or hematopoietic stem cell transplantation.
- •Gastrointestinal bleeding requiring surgical treatment, intestinal ischemia, or perforation.
- •Any of the following events within 6 months prior to screening: deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina pectoris; percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, or cerebral embolism.
- •Diagnosis of another primary malignancy within 5 years prior to screening, except curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected carcinoma in situ.
- •Pleural effusion, pericardial effusion, or ascites that remains uncontrolled despite drainage or requires repeated drainage.
- •Surgical complications or delayed wound healing prior to screening that, in the investigator's judgment, would increase the risk of study treatment.
- •13Severe respiratory disease. 14.Known leptomeningeal metastasis; symptomatic central nervous system (CNS) metastases. Participants with previously treated brain metastases who are clinically stable (as confirmed by MRI) for at least 12 weeks may be enrolled.
- •15.Any uncontrolled clinical condition. 16.Active autoimmune disease requiring systemic treatment during the study. 17.Presence of acute or chronic infection. 18.Pregnant or breastfeeding women. 19.Known psychiatric illness, alcoholism, drug abuse, or substance abuse. 20.Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
结局指标
主要结局
safety and tolerability
时间窗: 1 year
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as part of safety and tolerability assessment
次要结局
未报告次要终点
研究者
相似试验
撤回
不适用
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid TumorsAdvanced Solid TumorsNCT07534813Grit Biotechnology16
尚未招募
1 期
An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung CancerNSCLCNCT07685041Jiangsu Hansoh Pharmaceutical Co., Ltd.24
招募中
2 期
A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive GliomaGliomaAdultNCT07678684HighField Biopharmaceuticals Corporation30
尚未招募
1 期
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerHormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast CancerNCT07701941Daiichi Sankyo220
招募中
1 期
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal AdenocarcinomaNCT07622940Beijing Biotech36